REG - EKF Diagnostics Hldg - Trading Update

EKF Diagnostics HoldingsAnnouncement

29/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240129:nRSc1313Ba&default-theme=true

RNS Number : 1313B  EKF Diagnostics Holdings PLC  29 January 2024

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Trading Update

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics
business, provides an unaudited trading update for the year ended 31 December
2023 ("FY 2023").

 

The Company expects to report full-year revenues and adjusted EBITDA(1)
in-line with management expectations, reflecting continued steady growth from
the Point-of-Care division and β-HB sales. Cash, net of bank borrowings, as
at 31 December 2023, was £4.4m.

 

Good progress continues to be made in the Life Sciences division's
fermentation capacity expansion. Purchase orders for precision fermentation
services using the new facility have been received and the Company continues
to onboard a number of customers. The Board anticipates that a steady build-up
of revenues generated from the new fermentation capacity through 2024,
alongside maintained growth across Point-of-Care and β-HB sales.

 

EKF will announce its FY 2023 results in late March 2024 and provide further
insight to expected performance for the current financial year at that time.

 

(1)Earnings before interest, tax, depreciation and amortisation, excluding
exceptional items and share based payments.

 

 

 EKF Diagnostics Holdings plc                                 www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Julian Baines, Executive Chair / Stephen Young, CFO           Tel: +44 (0)29 2071 0570

 Singer Capital Markets (Nominated Adviser & Broker)                                        Tel: +44 (0)20 7496 3000
 Aubrey Powell / Oliver Platts

 Walbrook PR Limited              Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Alice Woodings    Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

 

EKF is an AIM-listed global diagnostics business focussed on:

 

·    Point-of-Care analysers in the key areas of Hematology and Diabetes,
as well as Central Laboratory products including clinical chemistry reagents,
analysers and centrifuges

 

·    Life Sciences services provide specialist manufacture of enzymes and
custom products for use in diagnostic, food and industrial applications, as
well as other higher value Contract Manufacturing services

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing
sites across the US and Germany, selling into over 120 countries world-wide.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTFLFIDLLITFIS